Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model마우스 모델에서 SARS-CoV-2 공격에 대한 보호 반응 유도에 대한 최적화된 서열과 SARS-CoV-2의 스파이크 단백질 야생형 DNA 서열의 비교Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 비임상, 진단, [키워드] acid Against Antiviral binding breath CD4 CD8+ cellular immune responses cellular immunity challenge clinical trial contributing to COVID-19 CTL demonstrated DNA DNA vaccine expression full-length spike protein hACE2 humoral humoral and cellular immunity IFN-γ immune immune responses immunogen in vitro induction mice Model mouse Neutralizing antibodies optimization optimizations pGX-9501 platform Protective Protective effects protective response RBD binding response robust SARS-CoV-2 sequence spike Spike protein subsequent T cell T cells the vaccine Transgenic mouse Type virus wild-type wild-type sequence. [DOI] 10.1080/21645515.2021.2016201 PMC 바로가기 [Article Type] Article
The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis후속 SARS-CoV-2 감염에 대한 자연 획득 항체의 보호: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Acquired Against analyses analysis antibody asymptomatic infection conducted COVID-19 COVID-19 case COVID-19 infection COVID-19 vaccination Efficacy eligible General population HCWs Health care worker incidence rate individual Infection Meta-analysis Naturally naturally acquired antibody naturally acquired immunity Newcastle-Ottawa Scale NOS Older outcome Population programming protection provided reduce Registration Reinfection reinfection. review risk SARS-CoV-2 SARS-COV-2 infection searched seropositive significant difference significantly specific antibody subsequent symptomatic was used [DOI] 10.1080/22221751.2022.2046446 PMC 바로가기 [Article Type] Meta-Analysis
Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 OmicronArticle Published on 2022-11-012022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome Against B.1.1.529 Beta Breakthrough infection coronavirus coronavirus 2 Delta Delta infection humoral immune response Infection neutralization neutralize Neutralizing activity neutralizing antibody omicron potent respiratory SARS-CoV-2 sera serum significant increase vaccination vaccination. Vaccine variant variants WA1 Wuhan-Hu-1 [DOI] 10.1093/infdis/jiac149 PMC 바로가기
Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States – IVY Network, 18 States, December 26, 2021-August 31, 2022Article Published on 2022-10-212022-11-16 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, [키워드] accounted Against B.1.1.529 booster dose category COVID-19 vaccine dose Effectiveness eligible adult estimate expected Hospitalization Immunity immunocompetent adult immunogenic include Infection Interpretation Lineage lineages majority monovalent mRNA mRNA component mRNA COVID-19 vaccine mRNA vaccine network omicron overlapped Period predominant Prevent protection receive reduce replaced SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain second dose the United State vaccination Vaccine Vaccine-induced immunity variant waned [DOI] 10.15585/mmwr.mm7142a3 PMC 바로가기
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance – VISION Network, 10 States, December 2021-August 2022Article Published on 2022-10-212022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] Against Analysis antibody antivirals B.1.1.529 benefit booster booster dose cause circulating Committee component conditions COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness eligible Hospitalization Hospitalized immunocompromising condition Mask moderate molecular test mRNA network nonpharmaceutical intervention offered omicron Person positive Practice predominant Prophylactic protection Protective receive recipient recommendation recommendations reduced Restricting SARS-CoV-2 therapy vaccination Vaccine variant virus [DOI] 10.15585/mmwr.mm7142a4 PMC 바로가기
Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2Article Published on 2022-10-172022-11-16 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Admission Against booster coronavirus coronavirus 2 COVID-19 Cox proportional hazard Czech Republic declined Delta Effectiveness evade Hospitalization Immunity Infection infections intensive care Logistic regression need for oxygen Odds ratio omicron Omicron variant outcome oxygen Postinfection postinfection immunity protection reached recent respiratory risk SARS-CoV-2 therapy vaccination Vaccine vaccine effectiveness. variant [DOI] 10.1093/infdis/jiac161 PMC 바로가기
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine BoosterArticle Published on 2022-10-172022-11-15 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Against binding antibody booster booster dose Breakthrough infection caused clinical trial coronavirus coronavirus 2 coronavirus disease COVID-19 Efficacy Level Neutralizing neutralizing antibody omicron Protein Receptor-binding domain respiratory responses SARS-CoV-2 SARS-CoV-2 variants subunit Support symptomatic the receptor-binding domain vaccination Vaccine vaccine candidate Vaccines variant Variant. variants [DOI] 10.1093/infdis/jiac241 PMC 바로가기
Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA VaccinationArticle Published on 2022-10-172022-11-15 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] activity acute respiratory syndrome Against BNT162b2 convalescent convalescent patient coronavirus coronavirus disease COVID-19 cross-neutralizing cross-neutralizing antibody dose evaluated induce mRNA mRNA vaccination mRNA-1273 Neutralizing antibody titer omicron Omicron. Received SARS-CoV-2 SARS-CoV-2 variants second vaccination seropositive severity subject the disease variant [DOI] 10.1093/infdis/jiac178 PMC 바로가기
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, CanadaArticle Published on 2022-10-032022-11-16 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] 95% CI adjusted Against age Care case-control study conducted dose doses Estimated female genomic greater Health Heterologous Hospitalization individual individuals Infection laboratory-confirmed laboratory-confirmed SARS-CoV-2 infection messenger Messenger RNA mRNA mRNA vaccination mRNA vaccine Odds ratio Older omicron outcome participant Participants phylogenetically Postinfection Prevent protection provided quantification Quebec, Canada reduction Reinfection risk risk reduction SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant severity Sex significantly higher stratified Surveillance tested vaccinated individual vaccination Vaccine vaccine dose vaccine strain variant [DOI] 10.1001/jamanetworkopen.2022.36670 PMC 바로가기
Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March-April 2021Article Published on 2022-10-032022-11-16 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, [키워드] Against B.1.351 Beta coronavirus 2 COVID-19 COVID-19 outbreak Effectiveness genomic sequencing mRNA mRNA vaccine Nursing patients prevention of COVID-19 respiratory SARS-CoV-2 Sequence analysis skilled nursing facility specimen vaccination Vaccine vaccine effectiveness. variant Virginia was performed [DOI] 10.1093/cid/ciac526 PMC 바로가기